

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Donepezil, galantamine, rivastigmine and memantine for the treatment of 'mild to moderate' Alzheimer's disease (part review of TA 111)

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Eisai Ltd (donepezil)</li> <li>• Novartis Pharmaceuticals (rivastigmine)</li> <li>• Shire Pharmaceuticals (galantamine)</li> <li>• Lundbeck Ltd (memantine)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Alzheimer's Society</li> <li>• Black Health Agency</li> <li>• Carers UK</li> <li>• Chinese National Healthy Living Centre</li> <li>• Confederation of Indian Organisations</li> <li>• Counsel and Care</li> <li>• Dementia Care Trust</li> <li>• Equalities National Council</li> <li>• Mental Health Foundation</li> <li>• MIND</li> <li>• Muslim Council of Great Britain</li> <li>• Muslim Health Network</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• The Neurological Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of British Neurologists</li> <li>• British Association for Services to the Elderly</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Commissioning Support Unit - Appraisals</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Public Health Service for Wales</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• NHS Purchasing and Supply Agency</li> <li>• NHS Quality Improvement Scotland</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Eisai Ltd (donepezil)</li> <li>• Novartis Pharmaceuticals (rivastigmine)</li> <li>• Shire Pharmaceuticals (galantamine)</li> <li>• Lundbeck Ltd (memantine)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Alzheimer's Research Trust</li> <li>• Institute for Ageing and Health</li> <li>• Institute of Psychiatry</li> <li>• National Institute for Health Research</li> </ul>

National Institute for Health and Clinical Excellence

Donepezil, galantamine, rivastigmine and memantine for the treatment of mild to moderate Alzheimer's disease (part review of TA 111)

Issue date: September 2009

## APPENDIX B

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Geriatrics Society</li> <li>• British Neuropsychiatry Association</li> <li>• For Dementia</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists (kidney, liver, cancer)</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• Islington PCT</li> <li>• West Kent PCT</li> <li>• Welsh Assembly Government</li> </ul>	<ul style="list-style-type: none"> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• Peninsula Technology Assessment Group, University of Exeter</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guidelines Centre</li> <li>• National Collaborating Centre for Mental Health</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• tbc</li> </ul>

- NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

### ***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

National Institute for Health and Clinical Excellence

Donepezil, galantamine, rivastigmine and memantine for the treatment of mild to moderate Alzheimer's disease (part review of TA 111)

Issue date: September 2009

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

#### Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing

National Institute for Health and Clinical Excellence

Donepezil, galantamine, rivastigmine and memantine for the treatment of mild to moderate Alzheimer's disease (part review of TA 111)

Issue date: September 2009